Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Harvard Business School
Express Scripts
Baxter
Chubb
Daiichi Sankyo
Mallinckrodt
UBS
Covington
Cantor Fitzgerald
Julphar

Generated: August 19, 2017

DrugPatentWatch Database Preview

Methotrexate - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for methotrexate and what is the scope of methotrexate freedom to operate?

Methotrexate
is the generic ingredient in fourteen branded drugs marketed by Antares Pharma Inc, Medac Pharma Inc, Silvergate Pharms, Zydus Pharms Usa Inc, Accord Hlthcare, Hospira, Abraxis Pharm, Mylan Labs Ltd, Sandoz Inc, West-ward Pharms Int, Duramed Pharms Barr, Mylan, Pharmacia And Upjohn, Pharmachemie Bv, Norbrook, Hq Spclt Pharma, Abic, Pharmachemie Usa, Bristol, Bristol Myers, Fresenius Kabi Usa, Dava Pharms Inc, Barr, and Bristol Myers Squibb, and is included in forty-seven NDAs. There are fifteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Methotrexate has fifty-eight patent family members in twenty-one countries.

There are twenty drug master file entries for methotrexate. Two suppliers are listed for this compound.

Summary for Generic Name: methotrexate

Tradenames:14
Patents:15
Applicants:24
NDAs:47
Drug Master File Entries: see list20
Suppliers / Packagers: see list2
Bulk Api Vendors: see list74
Clinical Trials: see list1,618
Patent Applications: see list106,509
Therapeutic Class:Immunological Agents
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:methotrexate at DailyMed

Pharmacology for Ingredient: methotrexate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abraxis Pharm
METHOTREXATE SODIUM
methotrexate sodium
INJECTABLE;INJECTION088935-001Oct 11, 1985DISCNNoNo► Subscribe► Subscribe► Subscribe
Pharmacia And Upjohn
FOLEX PFS
methotrexate sodium
INJECTABLE;INJECTION081242-001Aug 23, 1991DISCNNoNo► Subscribe► Subscribe► Subscribe
Pharmacia And Upjohn
FOLEX PFS
methotrexate sodium
INJECTABLE;INJECTION089180-001Jan 3, 1986DISCNNoNo► Subscribe► Subscribe► Subscribe
West-ward Pharms Int
METHOTREXATE SODIUM PRESERVATIVE FREE
methotrexate sodium
INJECTABLE;INJECTION040632-001Aug 12, 2005RXNoYes► Subscribe► Subscribe► Subscribe
Antares Pharma Inc
OTREXUP
methotrexate
SOLUTION;SUBCUTANEOUS204824-007Mar 24, 2016RXYesNo► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: methotrexate

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,180,259Prefilled syringe jet injector► Subscribe
6,565,553 Needle assisted jet injector► Subscribe
6,428,528 Needle assisted jet injector► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: methotrexate

Country Document Number Estimated Expiration
Serbia51688► Subscribe
Mexico2009000812► Subscribe
BrazilPI0614025► Subscribe
Japan2009544636► Subscribe
European Patent Office2408493► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

US Department of Justice
Citi
Accenture
Healthtrust
Daiichi Sankyo
Colorcon
Harvard Business School
Medtronic
Boehringer Ingelheim
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot